Last reviewed · How we verify
BAT3306
BAT3306 is a monoclonal antibody targeting PD-1.
BAT3306 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | BAT3306 |
|---|---|
| Also known as | Pembrolizumab Injection |
| Sponsor | Bio-Thera Solutions |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BAT3306 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants (PHASE1)
- A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC (PHASE3)
- Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |